New trends in HIV treatment
Currently, more than 40 million HIV-positive individuals live worldwide. Since the first isolation of the virus in 1983, there has been a real revolution in the diagnosis and treatment of HIV infection. However, despite significant advances in antiretroviral therapy, HIV infection remains incurable. This review presents the most promising developments in HIV treatment.Popova A.A., Deulina M.O., Pokrovskaya A.V., Akimkin V.G.
Keywords
HIV infection
therapy
antiretroviral therapy
ART
extended-release drugs
References
1. Адгамов Р.Р., Антонова А.А., Огаркова Д.А., Кузнецова А.И., Почтовый А.А., Клейменов Д.А. и др. ВИЧ-инфекция в Российской Федерации: современные тенденции диагностики. ВИЧ-инфекция и иммуносупрессии 2024; 16(1): 45–59. [Adgamov R.R., Antonova A.A., Ogarkova D.A., Kuznetsova A.I., Pochtovyi A.A., Kleymenov D.A. et al. HIV-infection in the Russian Federation: current diagnostic trends. HIV Infection and Immunosuppressive Disorders 2024; 16(1): 45–59. (In Russ.)]. DOI: 10.22328/2077-9828-2024-16-1-45-59
2. Bongiovanni M., Casana M., Tincati C., d’Arminio Monforte A. Treatment interruptions in HIV-infected subjects. J. Antimicrob. Chemother. 2006; 58(3): 502–505. DOI: 10.1093/jac/dkl268
3. Квасов Н.А., Полякова А.К., Лопатухин А.Э., Мурзакова А.В., Шемшура А.Б., Киреев Д.Е. Метод измерения размера клеточного резервуара ВИЧ и определение его у пациентов без опыта приема АРТ. Эпидемиол. инфекц. болезни. Актуал. вопр. 2021; 11(4): 66–72. [Kvasov N.A., Polyakova A.K., Lopatukhin A.E., Murzakova A.V., Shemshura A.B., Kireev D.E. Method for measurement of the size of the HIV cell reservoir and for its determination in patients who are not experienced with ART. Epidemiology and infectious diseases. Current items 2021; 11(4): 66–72 (In Russ.)]. DOI: 10.18565/epidem.2021.11.4.66-72
4. Jogiraju V., Pawar P., Yager J., Ling J., Shen G., Chiu A. et al. Pharmacokinetics and safety of once-yearly lenacapavir: a phase 1, open-label study. Lancet 2025; 405(10485): 1147–1154 DOI: 10.1016/S0140-6736(25)00405-2
5. Кравченко А.В., Юрин О.Г., Покровская А.В. 25 лет применения отечественных оригинальных антиретровирусных препаратов в схемах первой линии терапии ВИЧ-инфекции. Инфекционные болезни: новости, мнения, обучение 2023; 12(2): 75–82. [Kravchenko A.V., Yurin O.G., Pokrovskaya A.V. 25 years of the use of domestic original antiretroviral drugs in first-line ART regimens of HIV-infection. Infectious Diseases: News, Opinions, Training. 2023; 12(2): 75–82. (In Russ.)]. DOI: 10.33029/2305-3496-2023-12-2-75-82
6. Abd-Ellah H.S., Mudududdla R., Carter G.Р., Baell J.B. Novel Perspectives on the Design and Development of a Long-Acting Subcutaneous Raltegravir Injection for Treatment of HIV – in vitro and in vivo Evaluation. Pharmaceutics 2023; 15(5): 1530. DOI: 10.3390/pharmaceutics15051530
7. Gillespie G., Carstens R.P., Zang X., Vargo R., Kapoor Y., Bhattacharyya A. et al.; Safety and Pharmacokinetics of MK‐8527 in Adults Without HIV. Clin. Transl. Sci. 2025; 18(9): e70331. DOI: 10.1111/cts.70331
8. Ankrom W., Rudd D.J., Schaeffer A., Panebianco D., Friedman E.J., Tomek C. et al.; Pharmacokinetic and Safety Profile of the Novel HIV Nonnucleoside Reverse Transcriptase Inhibitor MK-8507 in Adults without HIV. Antimicrob. Agents Chemother. 2021; 65(12): e00935-21. DOI: 10.1128/AAC.00935-21
9. Zhang H., Mendes I., Mortensen E., Wang H., Share A., Sobczyk M. et al.; Pharmacokinetics and Safety of GS-1720 Following Multiple Ascending Doses in a Phase 1a Study in People Without HIV-1. Open Forum Infect. Dis. 2025; 12(Suppl 1): ofae631.040. DOI: 10.1093/ofid/ofae631.040
10. Olagunju A., Perazzolo S., Stephen Z.R., Ryan M., Xu X., Prajith Venkatasubramanian et al.; The Promises and Prospects of Long-Acting Therapeutics for Treatment and Prevention of Infectious Diseases. Annu. Rev. Pharmacol. Toxicol. 2025; 66(1): 87–112. DOI: 10.1146/annurev-pharmtox-071724-100739
11. Wang Q., Zhang L. Broadly neutralizing antibodies and vaccine design against HIV-1 infection. Front. Med. 2020; 14(1): 30–42. DOI: 10.1007/s11684-019-0721-9
12. Немудрый А.А., Валетдинова К.Р., Медведев С.П., Закиян С.М. Системы редактирования геномов TALEN и CRISPR/Cas – инструменты открытий. Acta Naturae 2014; (6): 20–42. [Nemudriy A.A., Valetdinova K.R., Medvedev S.P., Zakian S.M. Genome editing systems TALEN and CRISPR/Cas – tools for discovery. Acta Naturae 2014; (6): 20–42. (In Russ.)]
13. Ebina H., Misawa N., Kanemura Y., Koyanagi Y. Harnessing the CRISPR/Cas9 system to disrupt latent HIV-1 provirus. Sci. Rep. 2013; (3): 2510.
14. Попова А.А., Покровская А.В. Текущее состояние разработки вакцин для профилактики ВИЧ-инфекции. Материалы IX Санкт-Петербургского форума по ВИЧ-инфекции с международным участием, посвященного 35-летию СПБ Центра по профилактике и борьбе со СПИД и инфекционными заболеваниями, Санкт-Петербург, 03–04 октября 2024 г. СПб: Человек и его здоровье, 2024: 47–54. [Popova A.A., Pokrovskaya A.V. Current status of vaccine development for the prevention of HIV infection. Proceedings of the IX St. Petersburg International HIV Forum, dedicated to the 35th Anniversary of the St. Petersburg AIDS Center, St. Petersburg, October 3–4, 2024. St. Petersburg: Chelovek i ego zdorovye, 2024: 47–54. (In Russ.)]
About the Authors
Anna A. Popova, Cand. Med. Sci., Senior Researcher, Department of Specialized Research laboratory for AIDS Epidemiology and Prevention, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being; Associate Professor, Department of Infectious Diseases, Russian Medical Academy of Continuous Professional Education, Ministry of Health of the Russia, Moscow, Russia; asya-med@mail.ru; https://orcid.org/0000-0001-9484-5917Marina O. Deulina, Biologist, Department of Specialized Research Laboratory for AIDS Epidemiology and Prevention, Central Research Institute of Epidemiology, Russian Federal Service for Surveillance on Consumer Rights Protection and Human Well-Being, Moscow, Russia; deulina@cmd.su; https://orcid.org/0009-0008-2730-9581
Anastasia V. Pokrovskaya, МD., Senior Researcher, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being; Professor, Department of Infectious Diseases with Courses of Epidemiology and Phthisiology, Medical Institute, RUDN University, Moscow, Russia; pokrovskaya@cmd.su; http://orcid.org/0000-0002-2677-0404
Professor Vasily G. Akimkin, Academician of the Russian Academy of Sciences, MD, Director, Central Research Institute of Epidemiology, Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being, Moscow, Russia; vgakimkin@yandex.ru; http://orcid.org/0000-0003-4228-9044
Similar Articles
